(NYSE: CRL) Charles River Laboratories International's forecast annual revenue growth rate of 2.34% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 5.48%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 24.86%.
Charles River Laboratories International's revenue in 2025 is $4,028,615,000.On average, 19 Wall Street analysts forecast CRL's revenue for 2025 to be $198,382,351,518, with the lowest CRL revenue forecast at $190,065,155,436, and the highest CRL revenue forecast at $209,307,899,034. On average, 19 Wall Street analysts forecast CRL's revenue for 2026 to be $203,205,340,962, with the lowest CRL revenue forecast at $192,821,149,404, and the highest CRL revenue forecast at $215,459,671,284.
In 2027, CRL is forecast to generate $213,540,318,342 in revenue, with the lowest revenue forecast at $198,333,137,340 and the highest revenue forecast at $235,686,698,442.